Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03909334 · ClinicalTrials.gov registry record · Phase 2
Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 study of Non-Small Cell Lung Cancer and Advanced Cancer, sponsored by Xiuning Le.
- Active
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 12
- Study locations
NCT03909334 is a Phase 2 study of Non-Small Cell Lung Cancer and Advanced Cancer that is active but no longer recruiting, run by Xiuning Le. The registered enrollment target is 160 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (76% lower). The trial reports 12 study locations across 10 states.
The verdict
NCT03909334, a Phase 2 study of Non-Small Cell Lung Cancer and Advanced Cancer, is active but no longer recruiting, sponsored by Xiuning Le.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 12
- Study locations
Study Summary
The primary objective of the study is to evaluate the efficacy of osimertinib plus ramucirumab versus osimertinib alone using progression free survival (PFS). Events associated with PFS include: disease progression per RECIST 1.1 and death due to any cause. A total of 150 patients will be enrolled and randomized in a 2:1 fashion (osimertinib plus ramucirumab vs. osimertinib) to the two treatment arms according to the following stratification factors: types of epidermal growth factor receptor (EGFR) mutations and presence of brain metastasis.
Conditions Studied
Interventions
- DRUG Osimertinib
- DRUG Ramucirumab
Study Locations (12)
Illinois
- Northwestern University Feinberg School of Medicine - Chicago
- Rush University Medical Center - Chicago
New York
- New York University Cancer Center - New York
- Columbia University Irving Medical Center - New York
District of Columbia
- Georgetown University - Washington D.C.
Florida
- Moffitt Cancer Center - Tampa
Indiana
- Indiana Univesity Melvin and Bren Simon Cancer Center - Indianapolis
New Jersey
- Summit Medical Group, PA - Berkeley Heights
Oregon
- Providence Portland Medical Center - Portland
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2019-07-25 |
| Est. Completion | 2026-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03909334
The ClinicalTrials.gov registry entry for NCT03909334 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (76% lower). The listed sponsor is Xiuning Le, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Osimertinib is the first listed.
NCT03909334 reports 12 study locations spanning 10 distinct geographic areas - top geographies include Illinois, New York, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT03909334 about?
NCT03909334 is a clinical study titled "Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)". The primary objective of the study is to evaluate the efficacy of osimertinib plus ramucirumab versus osimertinib alone using progression free survival (PFS). Events associated with PFS include: disease progression per RECIST 1.1 and death due to any cause. A total of 150 patients will be enrolled a...
What is the current status of trial NCT03909334?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2019-07-25. Estimated completion is 2026-01.
What conditions does trial NCT03909334 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Advanced Cancer, Metastatic Cancer, EGFR Gene Mutation.
What interventions are being tested in trial NCT03909334?
The interventions under investigation include: Osimertinib (DRUG), Ramucirumab (DRUG).
Who is sponsoring clinical trial NCT03909334?
This trial is sponsored by Xiuning Le, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03909334 being conducted?
This trial has 12 study locations across District of Columbia, Florida, Illinois, Indiana, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Non-Small Cell Lung Cancer
All registered trials for this condition
Advanced Cancer
All registered trials for this condition
District of Columbia
All trials with a study site in District of Columbia
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.